AzurRx BioPharma Receives Insititutional Review Board Approval to Commence its Phase 2 OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis
AzurRx BioPharma, Inc. (AZRX)
Last azurrx biopharma, inc. earnings: 11/14 04:31 pm
Check Earnings Report
US:NASDAQ Investor Relations:
azurrx.com/index.php/investors/investor-relations
Company Research
Source: GlobeNewswire
IRB protocol approval provides green-light to initiate trial at U.S. clinical sites NEW YORK, April 30, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that it has received Institutional Review Board (IRB) approval of its Phase 2 OPTION 2 clinical trial protocol to investigate MS1819 in cystic fibrosis (CF) patients with exocrine pancreatic insufficiency (EPI). “We are very pleased to receive IRB approval and look forward to entering the clinic,” said James Pennington, M.D., Chief Medical Officer of AzurRx. “We believe it is important to have a synthetic recombinant alternative to the current porcine derived PERT treatment, and optimizing our MS1819 dose is one more step forward towards realizing this goal. We look forward to working with our clinical collaborators and participating patients to test the effic
Show less
Read more
Impact Snapshot
Event Time:
AZRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AZRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AZRX alerts
High impacting AzurRx BioPharma, Inc. news events
Weekly update
A roundup of the hottest topics